Danaher Corp (DHR) Stock Analysis
Verdict: WATCH (do not buy)
Bioprocessing recovery is priced as a certainty despite recent technical breakdown and stalling EPS growth — value exists at $165 support.
Investment score: 58/100
Analysis as of
Is Danaher Corp stock worth reviewing? AI model thesis
Danaher is an elite compounder currently undergoing a painful technical correction. The model suggests holding while waiting for a base to form near its 52-week low of $160.93.
7-factor investment score
- Valuation: 55/100 (weight 20%)
- Financial Health: 85/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 50/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 65/100 (weight 10%)
- Risk-Adjusted Return: 60/100 (weight 15%)
Danaher Corp opportunities and risks
What speaks for DHR
- Bioprocessing Recovery Tailwinds
What speaks against DHR
- Broken Technical Momentum and High Volume Selling
Frequently asked questions about Danaher Corp (DHR)
Is DHR stock a good investment?
The cached TradeMates AI model rates Danaher Corp as WATCH (do not buy) with an investment score of 58/100. Danaher is an elite compounder currently undergoing a painful technical correction. The model suggests holding while waiting for a base to form near its 52-week low of $160.93. This is algorithmic model output, not personal investment advice.
Is DHR stock a buy?
The TradeMates model verdict for DHR is WATCH (do not buy) with an investment score of 58/100. Treat this as a model signal to review, not a personal buy recommendation.